Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 8/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | FGF1 | P05230 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 2/20 | 0.37 |
| ▸ | SI | P14410 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121030 | 1.00 | LGALS8 (0.47) | LGALS8F10CA2CA9CA1 | |
| SCHEMBL29535299 | 0.83 | MAPK1 (0.40) | LGALS8F10CA2CA9CA1 | |
| SCHEMBL16728933 | 0.83 | MAPK1 (0.40) | LGALS8F10CA2CA9CA1 | |
| SCHEMBL1893622 | 0.83 | FGF1 (0.51) | LGALS8F10CA2CA9CA1 | |
| SCHEMBL7533468 | 0.83 | LGALS8 (0.57) | LGALS8CA2CA9CA1FGF1 | |
| SCHEMBL7533461 | 0.83 | LGALS8 (0.57) | LGALS8CA2CA9CA1FGF1 | |
| SCHEMBL14641263 | 0.83 | FGF1 (0.51) | LGALS8F10CA2CA9CA1 | |
| SCHEMBL28577159 | 0.77 | LGALS8 (0.47) | LGALS8F10FGF1MGAMSI | |
| SCHEMBL29535345 | 0.75 | LGALS3 (0.38) | F10CA2CA9CA1LGALS3 | |
| SCHEMBL25505005 | 0.74 | FGF1 (0.53) | LGALS8CA2CA9CA1FGF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589757-B1 | Labeling/tagging the reducing ends; depolymerisation using a selection scission reagent; treated with exoenzymes (exoglycosidases) that cleave only particular glycosidic linkages | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-07-08 | — | — | US | disclosed |
| WO-2000001843-A1 | SEQUENCE ANALYSIS OF SACCHARIDE MATERIAL | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0788554-B1 | SEQUENCE ANALYSIS OF SACCHARIDE MATERIAL | CANCER RES CAMPAIGN TECH (GB) | 2000-01-12 | — | — | EP | disclosed |
| US-5808021-A | Method for controlling O-desulfation of heparin | GLYCOMED INCORPORATED (US) | 1998-09-15 | — | — | US | disclosed |
| US-5696100-A | ANTICANCER AGENT | GLYCOMED INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0788554-A1 | SEQUENCE ANALYSIS OF SACCHARIDE MATERIAL | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013606-A1 | SEQUENCE ANALYSIS OF SACCHARIDE MATERIAL | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-09 | — | — | WO | disclosed |
| US-5296471-A | Unfragmented 2-O, 3-O desulfated mucosal heparin or fragments | GLYCOMED INCORPORATED (US) | 1994-03-22 | — | — | US | disclosed |